Cite
HARVARD Citation
Adenis, A. et al. (2022). Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. Journal of clinical oncology. 40 (4), pp. 382-391. [Online].